bioRxivMicrobiologyPreprint
Increased receptor binding capability of the SARS-CoV-2 saltational variant PJ.2.1
Peizhuo He, BingKun Li, Caiwan GuoiD, Lingling YuiD, Yuanling YuiD, Fanchong JianiD, Fei Shao, Yunlong CaoiD
Abstract
The recently identified SARS-CoV-2 saltational variant PJ.2.1, a highly mutated descendant of MC.10.1, has achieved rapid intercontinental spread since its detection in May 2026. Here, we show that PJ.2.1 exhibits exceptionally high human ACE2-binding capability, significantly outperforming contemporary variants such as NB.1.8.1, XFG, and BA.3.2.2. However, despite acquiring over 25 spike mutations, PJ.2.1 remains antigenically similar to the circulating JN.1 family and does not display strong humoral immune evasion. Neutralization profiling indicates that PJ.2.1 possesses heightened neutralization sensitivity to human plasma and RBD-targeting antibodies, especially against cryptic-site-targeting class 4 and class 5 antibodies. This distinct sensitivity profile strongly suggests an altered spike structural dynamic that favors a receptor-accessible "up" conformation. While PJ.2.1 currently lacks the extreme immune evasion capabilities of other contemporary strains, its robust baseline receptor binding strength mirrors the early evolutionary trajectory of BA.2.86 to JN.1. This high receptor binding affinity provides a structural buffer that could facilitate the rapid acquisition of potent immune-evasive mutations, necessitating continued genomic, epidemiological, and virological surveillance of PJ.2.1.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: protein folding & dynamics
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epidemiology and virological characteristics of the emerging SARS-CoV-2 variant PJ.2.1
Markus Hoffmann, Lu Zhang, … Stefan Poehlmann·bioRxiv·Oct 8, 2026
- Antibody evasion and receptor binding of SARS-CoV-2 variants PQ.16.1.1 and RK.1
Peizhuo He, Yunwen Song, … Yunlong Cao·The Lancet Infectious DiseasesPeer-reviewed·Aug 13, 2026
- Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1
- SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility
M. Vogel, X. Chang, … M. F. Bachmann·bioRxiv·Mar 4, 2021
- Antibody evasion and receptor binding of SARS-CoV-2 RW.1.1
Kristin Daniel, Hsiang Hong, … Ian A. Mellis·bioRxiv·Sep 18, 2026
- Mutation-induced Changes in the Receptor-binding Interface of the SARS-CoV-2 Delta Variant B.1.617.2 and Implications for Immune Evasion
P. Baral, N. Bhattarai, … P. P. Chapagain·bioRxiv·Jul 17, 2021